Eli Lilly and Company
Health
Performance
4.4
Risk
Sell
Buy
Curious about the Scores? Learn more.

Eli Lilly and Company stock rating and score history

All changes in ratings, performance and outlook tracked over time.

09.01.2026
Risk creeping up. Stability not bulletproof anymore.
01.01.2026
Back in top shape. Balance sheet solid, outlook sharp.
02.11.2025
Max level achieved. Once more ahead of all the rest.
02.11.2025
Outperforming hard. Momentum locked in.

Eli Lilly and Company stock price, chart patterns and momentum

Recent price movements, trend behaviour and momentum signals based on real-time market data.

What does Eli Lilly and Company do? Business model and key facts

Get the full picture of Eli Lilly and Company: what it builds, where it operates, and how it makes money.

Eli Lilly and Company Profile

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees (FY): 47000

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

shop
Company facts
Lucas E. Montarce
CEO
47000
Employees worldwide
shop
Performance
35.07%
Last 12 months
480.7%
Last 5 years
shop
Growth
$45,04B
Revenue year
$10,59B
Net income
shop
Valuation
$927,90B
Market Cap
65.65
Price/Earnings Ratio

Stocks related to Eli Lilly and Company

Selected based on industry alignment and relative market positioning.

JNJ
Low-poly 3D Johnson & Johnson (JNJ) stock icon with a stylized medical cross, symbolizing healthcare and biotech.
219.57
+0.47%
2.2
Sell
Buy
Johnson & Johnson
ABBV
Low-poly 3D AbbVie (ABBV) stock icon with a stylized molecule, symbolizing healthcare and biotech.
216.75
-2.32%
2.7
Sell
Buy
AbbVie Inc.
AZN
Low-poly 3D AstraZeneca (AZN) stock icon with a stylized molecule, symbolizing healthcare and biotech.
93.99
-2.44%
2.4
Sell
Buy
AstraZeneca PLC
NVS
Low-poly 3D Novartis (NVS) stock icon with a stylized pill capsule, symbolizing healthcare and biotech.
143.15
-2.06%
1.7
Sell
Buy
Novartis AG
MRK
Low-poly 3D Merck (MRK) stock icon with a stylized molecule, symbolizing healthcare and biotech.
110.96
-0.05%
3.2
Sell
Buy
Merck & Co., Inc.

Eli Lilly and Company fundamentals and technical analysis

Financial fundamentals and technicals signals combined to access stability, momentum and market direction.